Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Purchases $148,000.00 in Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Raymond Debbane purchased 100,000 shares of the firm’s stock in a transaction on Friday, February 20th. The shares were purchased at an average price of $1.48 per share, for a total transaction of $148,000.00. Following the completion of the purchase, the director directly owned 1,804,186 shares of the company’s stock, valued at $2,670,195.28. This represents a 5.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Raymond Debbane also recently made the following trade(s):

• On Thursday, February 19th, Raymond Debbane acquired 50,000 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average cost of $1.44 per share, with a total value of $72,000.00.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX opened at $1.53 on Monday. The company has a market cap of $557.56 million, a P/E ratio of -7.96 and a beta of 0.98. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $1.83. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47. The firm’s 50 day moving average price is $1.29 and its 200 day moving average price is $1.30.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Hudson Bay Capital Management LP acquired a new stake in Lexicon Pharmaceuticals in the 2nd quarter valued at about $26,000. R Squared Ltd acquired a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at $28,000. Security National Bank of Sioux City Iowa IA acquired a new stake in Lexicon Pharmaceuticals in the 4th quarter worth about $31,000. Leonteq Securities AG acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $34,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth $39,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.23.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.